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INTRODUCTION 
 Dengue viral infection is the most common mosquito borne disease in the 
world with varied presentations, high morbidity and high mortality patterns. 2.5 
billion people – two fifths of the world's population in tropical and subtropical 
countries are at risk 1 . An estimated 50 million dengue infections occur 
worldwide annually. A very large proportion (approximately 90%) of them are 
children aged less than five years, and about 2.5% of those affected die.                     
Epidemics of dengue are increasing in frequency. During epidemics, infection 
rates among those who have not been previously exposed to the virus are often 
40% to 50% but can also reach 80% to 90%.  Aedes (Stegomyia) aegypti is the 
primary epidemic vector. 
 Primarily an urban disease, dengue and DHF are now spreading to rural 
areas worldwide. Dengue viral infections classified on the basis of WHO 
criteria2  as follows: 
1. Dengue fever (DF): Dengue seropositive without bleed. 
2. Dengue fever with unusual bleed (DFB): Dengue seropositive with 
bleeding tendencies, not satisfying WHO criteria for DHF. 
3. Dengue hemorrhagic fever (DHF): Dengue seropositive with bleeds with 
evidence of plasma leakage. 
4. Dengue shock syndrome (DSS): DHF with evidence of peripheral 
circulatory failure.                                                                                         
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 Dengue generally an acute febrile illness, and sometimes biphasic fever 
with severe headache, myalgia, arthralgia, rashes, leucopenia and 
thrombocytopenia may also be observed. DHF is characterized by the acute 
onset of high fever and is associated with signs and symptoms similar to DF in 
the early febrile phase. There are common haemorrhagic manifestation such as 
positive tourniquet test (TT), petechiae, easy bruising and/or GI haemorrhage in 
severe cases. By the end of the febrile phase, there is a tendency to develop 
hypovolemic shock (dengue shock syndrome) due to plasma leakage. The 
presence of preceding warning signs such as persistent vomiting, abdominal 
pain, lethargy or restlessness, or irritability and oliguria are important for 
intervention to prevent shock.  
 Abnormal haemostasis and plasma leakage are the main patho- 
physiological hallmarks of DHF. Thrombocytopenia and rising haematocrit/ 
haemoconcentration are constant findings before the subsidence of fever/ onset 
of shock. DHF occurs most commonly in children with secondary dengue 
infection. It has also been documented in primary infections with DENV-1 and 
DENV-3 as well as in infants.We live in a country with resource limited settings 
confounded by public ignorance about the disease and poor access to health 
care. Severity is high in paediatric age group. 
 No vaccine is available for preventing this disease at present. 
Chandrakanta et  al3 describe the varied manifestations of dengue viral infection 
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as seen in hospitalized children in northern India. Manjunath J. Kulkarni et al4 
in their study describe various clinical manifestations.  
 The demographic pattern and the trend of illness are vastly changing 
every year through the past decade. South India and especially South Tamilnadu 
has witnessed several dengue epidemic outbreaks during the past few years. 
Early recognition and prompt initiation of appropriate management is vital. 
Additional studies about the disease can lead to change in guidelines and 
alterations in public health programs. Here, I have made an attempt to study the 
clinical profile and outcome of dengue viral infection the time period from Dec 
2009 to Dec 2010. 
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OBJECTIVE 
 
To study the clinical profile and outcome of dengue fever in children. 
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LITERATURE REVIEW 
 
EPIDEMIOLOGY: 
 Dengue is the most rapidly spreading mosquito-borne viral disease in the 
world. Dengue is an example of a disease that may constitute a public health 
emergency of international concern with implications for health security due to 
disruption and rapid epidemic spread beyond national borders5 . The global 
prevalence of dengue has grown dramatically in the last decade, with increasing 
geographic expansion to new countries AND, from urban to rural settings. The 
disease is now endemic in more than 100 countries in africa, the americas, the 
eastern mediterranean, southeast asia, and the western pacific, threatening more 
than 2.5 billion people6.Dengue is believed to infect 50 to 100 million people 
worldwide a year with half a million life-threatening infections requiring 
hospitalization, resulting in approximately 12,500 to 25,000 deaths. Over the 
past three decades, there has been a dramatic global increase in the frequency of 
dengue fever, and its severe forms- DHF and DSS and their epidemics .  
   There is no specific treatment for dengue, but appropriate medical care 
frequently saves the lives of patients with the more serious dengue 
haemorrhagic fever. The most effective way to prevent dengue virus 
transmission is to combat the disease-carrying mosquito1 
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 The first confirmed epidemic of DHF was recorded in the Philippines in 
1953–1954 and in Thailand in 1958. Since then,  several Member countries of 
the WHO have been reporting outbreaks.  
South-East Asia Region 
 Of the 2.5 billion people around the world living in dengue endemic 
countries and at risk of  contracting DF/DHF, 1.3 billion live in 10 countries of 
the WHO South-East Asia (SEA) Region which are dengue endemic areas. . 
Epidemic dengue is a major public health problem in most of these countries.By 
2009, all Member countries except the Democratic People’s Republic (DPR) of 
Korea reported dengue outbreaks. Reported case fatality rates for the region are 
approximately 1%, but in India, Indonesia and Myanmar, focal outbreaks away 
from the urban areas have reported case-fatality rates of 3--5%. The countries of 
the region have been divided into three distinct categories with different dengue 
transmission potential 
      INDIA falls under Category A which includes countries where dengue is 
a 
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  Major public health problem. 
  Leading cause of hospitalization and death among children. 
  Hyperendemicity with “all four serotypes” circulating in urban areas. 
  Spreading to rural areas. 
 Cyclic epidemics are increasing in frequency and in-country geographic 
expansion is occurring in  India. 
 Dengue prevention and control will be implemented through the Bi-
regional Dengue Strategy (2008--2015) of the WHO South-East Asia and 
Western Pacific regions7 
The virus 
 The dengue viruses are members of the genus Flavivirus and family 
Flaviviridae. These small (50nm) viruses contain single-strand RNA as 
genome. The virion consists of a nucleocapsid with cubic symmetry enclosed in 
a lipoprotein envelope. The dengue virus genome is 11,644 nucleotides in 
length, and is composed of three structural protein genes encoding the 
nucleocaprid or core protein (C), a membrane-associated protein (M), an 
envelope protein (E), and seven non-structural protein (NS) genes. Among 
nonstructural proteins, envelope glycoprotein, NS1, is of diagnostic and 
pathological importance. It is 45 kDa in size and associated with viral 
haemagglutination and neutralization activity.8 
 The dengue viruses form a distinct complex within the genus Flavivirus 
based on antigenic and biological characteristics. There are four virus serotypes, 
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which are designated as DENV-1, DENV-2,DENV-3 and DENV-4. Infection 
with any one serotype confers lifelong immunity to that virus serotype.Although 
all four serotypes are antigenically similar, they are different enough to elicit 
cross-protection for only a few months after infection by any one of them. 
Secondary infection with another serotype or multiple infections with different 
serotypes leads to severe form of dengue (DHF/DSS). 
 There exists considerable genetic variation within each serotype in the 
form of phylogenetically distinct “sub-types” or “genotypes”. Currently, three 
sub-types can be identified for DENV-1, six for DENV-2 (one of which is 
found in non-human primates), four for DENV-3 and four for DEN-4, with 
another DENV-4 being exclusive to non-human primates. Dengue viruses of all 
four serotypes have been associated with epidemics of dengue fever (with or 
without DHF) with a varying degree of severity.Among them, “Asian” 
genotypes of DEN-2 and DEN-3 are frequently associated with severe disease 
accompanying secondary dengue infections Intra-host viral diversity 
(quasispecies) has also been described in human9 
 Plasma levels of secreted NS1 (sNS1) correlate with viral titers, being 
higher in patients with DHF compared with dengue fever10 . Moreover, elevated 
free sNS1 levels within 72 hours of onset of illness identify patients at risk of 
developing DHF. Very high levels of NS1 protein are detected in acute phase 
samples from patients with secondary dengue infections but not primary 
infections. This suggests that NS1 may contribute to formation of circulating 
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immune complexes, which are thought to have an important role in the 
pathogenesis of severe dengue infections11 .The dengue virus shares antigenic 
epitopes with other flaviviruses such as Japanese encephalitis virus. These 
shared epitopes may lead to production of cross reactive antibodies and hence 
interfere with serological diagnosis. However,antibodies directed to the prM 
protein of dengue viruses are species specific (not cross reactive with those of 
other flaviviruses) and may be useful for seroepidemiological studies in dengue 
(especially in countries where other flaviviruses are endemic) 
Vectors of dengue 
 Aedes (Stegomyia) aegypti (Ae. aegypti) and Aedes (Stegomyia) 
albopictus (Ae. albopictus) are the two most important vectors of dengue                     
Aedes (Stegomyia) aegypti 
 
 Aedes aegypti is a container breeding, day biting mosquito  found in 
tropical and subtropical areas12. The immature stages are found in water-filled 
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habitats, mostly in artificial containers closely associated with human dwellings 
and often indoors. This maximizes man-vector contact and minimizes contact 
with insecticides sprayed outdoors, hence contributing to difficulty in 
controlling this vector13.  Studies suggest that most female Ae. aegypti may 
spend their lifetime in or around the houses where they emerge as adults. This 
means that people, rather than mosquitoes, rapidly move the virus within and 
between communities . Increased  transport, human contact, urbanization and 
the proliferation of drinking water supply schemes   in  rural areas ultimately led 
to the species getting entrenched in both urban and rural areas . On account of 
the species’ high degree of domestication and strong affinity for human blood, it 
achieved high vectorial capacity for transmission of DF/DHF.Significant 
increases in the mosquito larval populations are seen during the rainy season. 
This may be a reason why epidemics of dengue tend to coincide with the rainy 
season10.Furthermore,ambient temperature and relative humidity affect viral 
propagation in mosquitoes; rates being highest in climates resembling the rainy 
season10.  
 After biting an infected human, dengue viruses enter an adult female 
mosquito. The virus first replicates in the midgut, reaches the haemocoel and 
haemolymph, and then gains access to different tissues of the insect. After viral 
replication in the salivary glands, the infected mosquito can transmit the virus to 
another human11 . Compared with uninfected mosquitoes, infected ones take 
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longer to complete a blood meal. This may contribute to the efficiency of A 
.aegypti as a dengue viral vector. 
    Aedes (Stegomyia) albopictus belongs to the scutellaris group of 
subgenus Stegomyia. It is a predominant Asian species. Dengue outbreaks have 
also been attributed to Aedes albopictus, Aedes polynesiensis and several 
species of the Aedes scutellaris complex. Each of these species has a particular 
ecology, behaviour and geographical distribution. 
Clinical manifestations 
 Dengue is one disease entity with different clinical presentations and 
often with unpredictable clinical evolution and outcome14.Dengue infection is a 
systemic and dynamic disease. It has a wide clinical spectrum that includes both 
severe and non-severe clinical manifestations15 . Dengue virus infection may be 
asymptomatic or may cause undifferentiated febrile illness (viral syndrome), 
dengue fever (DF), or dengue haemorrhagic fever (DHF) including dengue 
shock syndrome(DSS)  
Undifferentiated fever 
 Infants, children and adults who have been infected with dengue virus, 
especially for the first time (i.e. primary dengue infection), may develop a 
simple fever indistinguishable from other viral  infections. Maculopapular 
rashes may accompany the fever or may appear during defervescence. 
Upper respiratory and gastrointestinal symptoms are common 
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Dengue fever 
 After the incubation period, the illness begins abruptly and is followed by 
the three phases -- febrile, critical and recovery . 
The course of dengue illness 
 
FEBRILE PHASE 
 Patients typically develop high-grade fever suddenly. This acute febrile 
phase usually lasts 2–7 days and is often accompanied by facial flushing, skin 
erythema, generalized body ache, myalgia, arthralgia and headache13. Some 
patients may have sore throat, injected pharynx and conjunctival injection. 
Anorexia, nausea and vomiting are common. It can be difficult to distinguish 
dengue clinically from non-dengue febrile diseases in the early febrile phase. A 
positive tourniquet test in this phase increases the probability of dengue 16. In 
addition, these clinical features are indistinguishable between severe and non-
severe dengue cases. Therefore monitoring for warning signs and other clinical  
13 
 
Facial flushing 
  
Facial rash and Subconjuctival hemorrage 
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parameters is crucial.Mild haemorrhagic manifestations like petechiae and 
mucosal membrane bleeding(e.g. nose and gums) may be seen 17 . Massive 
vaginal bleeding (in women of childbearing age) and gastrointestinal bleeding 
may occur during this phase but is not common 18. The liver is often enlarged 
and tender after a few days of fever15. The earliest abnormality in the full blood 
count is a progressive decrease in total white cell count, which should alert the 
physician to a high probability of dengue. 
 
CRITICAL PHASE: 
 Around the time of defervescence, when the temperature drops to 37.5–
38ºC or less and remains below this level, usually on days 3–7 of illness, an 
increase in capillary permeability in parallel with increasing haematocrit levels 
may occur19  This marks the beginning of the critical phase. The period of 
clinically significant plasma leakage usually lasts 24–48 hours. 
 Progressive leukopenia 15 followed by a rapid decrease in platelet count 
usually precedes plasma leakage. At this point patients without an increase in 
capillary permeability will improve, while those with increased capillary 
permeability may become worse as a result of lost plasma volume. The degree 
of plasma leakage varies. Pleural effusion and ascites may be clinically 
detectable depending on the degree of plasma leakage and the volume of fluid 
therapy. Hence chest x-ray and abdominal ultrasound can be useful tools for 
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diagnosis. The degree of increase above the baseline haematocrit often reflects 
the severity of plasma leakage. 
 Shock occurs when a critical volume of plasma is lost through leakage. It 
is often preceded by warning signs. The body temperature may be subnormal 
when shock occurs. With prolonged shock, the consequent organ hypoperfusion 
results in progressive organ impairment, metabolic acidosis and disseminated 
intravascular coagulation. This in turn leads to severe haemorrhage causing the 
haematocrit to decrease in severe shock. Instead of the leukopenia usually seen 
during this phase of dengue, the total white cell count may increase in patients 
with severe bleeding. In addition, severe organ impairment such as severe 
hepatitis, encephalitis or myocarditis and/or severe bleedingmay also develop 
without obvious plasma leakage or shock 20. 
 Some patients progress to the critical phase of plasma leakage without 
defervescence and, in these patients, changes in the full blood count should be 
used to guide the onset of the critical phase and plasma leakage. 
RECOVERY PHASE: 
 If the patient survives the 24–48 hour critical phase, a gradual 
reabsorption of extravascular compartment fluid takes place in the following 
48–72 hours.  
 General well-being improves, appetite returns, gastrointestinal symptoms 
abate, Haemodynamic status stabilizes and diuresis ensues. Some patients may 
have a rash of “isles of white in the sea of red”21. Some may experience 
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generalized pruritus. Bradycardia and electrocardiographic changes are common 
during this stage.The haematocrit stabilizes or may be lower due to the 
dilutional effect of reabsorbed fluid. White blood cell count usually starts to rise 
soon after defervescence but the recovery of platelet count is typically later than 
that of white blood cell count.Respiratory distress from massive pleural effusion 
and ascites will occur at any time if excessive intravenous fluids have been 
administered. During the critical and/or recovery phases, excessive fluid therapy 
is associated with pulmonary oedema or congestive heart failure. 
Febrile, critical and recovery phases in dengue 
 
 Dengue hemorrhagic fever 
 DHF usually follows secondary dengue infections, but may sometimes 
follow pimary infections, especially in infants. In such infants, maternally 
acquired dengue antibodies are presumed to enhance primary infections 22 . 
Clinical deterioration usually occurs during defervescence (often between days 
3 and 4). Tachycardia and hypotension characterize the onset of plasma leakage. 
When plasma leakage is severe patients may develop othersigns of circulatory 
disturbance such as prolonged capillary refill time, narrow pulse pressures, and 
shock. Inadequate treatment of such patients often leads to profound shock.In 
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DHF, bleeding may occur from any site and does not correlate with the platelet 
counts. 
 Haemorrhagic manifestations usually occur once the fever has settled.23 
Minor degrees of bleeding may manifest as gum bleeding and petechiae. The 
commonest site of haemorrhage is the gastrointestinal tract, which manifests as 
haematemesis or melaena, followed by epistaxis. Vaginal bleeding is commonly 
reported in females21. Convalescence in DHF is usually short and uneventful. 
The return of appetite is a good indicator of recovery. 
Dengue shock syndrome 
 Dengue shock syndrome is associated with very high mortality (around 
9.3%, increasing to 47% in instances of profound shock)24 . Severe plasma 
leakage leading to dengue shock syndrome is associated with cold blotchy skin, 
circumoral cyanosis, and circulatory disturbances. Acute abdominal pain and 
persisting vomiting are early warning signs of impeding shock. Sudden 
hypotension may indicate the onset of profound shock .Prolonged shock is often 
accompanied by metabolic acidosis, which may precipitate disseminated 
intravascular coagulation or enhance ongoing disseminated intravascular 
coagulation, which in turn could lead to massive haemorrhage. Dengue shock 
syndrome may be accompanied by encephalopathy due to metabolic or 
electrolyte disturbances. 
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COMPLICATIONS:  
 DHF AND DSS have been associated with increasing frequency in recent 
times with the following complications25 
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Differential diagnoses of dengue26 
 Arboviruses: Chikungunya virus (this has often been mistaken for 
dengue in South-East Asia). 
 Other viral diseases: Measles; rubella and other viral exanthems; 
Epstein-Barr Virus (EBV); enteroviruses; influenza; hepatitis A; 
Hantavirus. 
 Bacterial diseases: Meningococcaemia, leptospirosis, typhoid, 
melioidosis, rickettsial diseases, scarlet fever. 
 Parasitic diseases: Malaria. 
Pathogenesis of Dengue: 
 DHF occurs in a small proportion of dengue patients. Although DHF may 
occur in patients experiencing dengue virus infection for the first time, most 
DHF cases occur in patients with a secondary infection. 27  The association 
between occurrence of DHF/DSS and secondary dengue infections implicates 
the immune system in the pathogenesis of DHF. Both the innate immunity such 
as the complement system and NK cells as well as the adaptive immunity 
including humoral and cell mediated immunity are involved in this process28. 
Enhancement of immune activation, particularly during a secondary infection, 
leads to exaggerated cytokine response resulting in changes in vascular 
permeability. In addition, viral products such as NS1 may play a role in 
regulating complement activation and vascular permeability.29 
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 The plasma leakage is unique in that there is selective leakage of plasma 
in the pleural and peritoneal cavities and the period of leakage is short (24–48 
hours). Rapid recovery of shock without sequelae and the absence of 
inflammation in the pleura and peritoneum indicate functional changes in 
vascular integrity rather than structural damage of the endothelium as the 
underlying mechanism.Various cytokines with permeability enhancing effect 
have been implicated in the pathogenesis of DHF 30 .However, the relative 
importance of these cytokines in DHF is still unknown. Studies have shown that 
the pattern of cytokine response may be related to the pattern of cross-
recognition of dengue-specific T-cells. Cross-reactive T-cells appear to be 
functionally deficit in their cytolytic activity but express enhanced cytokine 
production including TNF-a, IFN-g and chemokines31. 
 Increase in vascular permeability can also be mediated by the activation 
of the complement system. Elevated levels of complement fragments have been 
documented in DHF.32Some complement fragments such as C3a and C5a are 
known to have permeability enhancing effects. In recent studies, the NS1 
antigen of dengue virus has been shown to regulate complement activation and 
may play a role in the pathogenesis of DHF27 
 Higher levels of viral load in DHF patients in comparison with DF 
patients have been demonstrated in many studies33. The levels of viral protein, 
NS1, were also higher in DHF patients34.The degrees of viral load correlate with 
measurements of disease severity. 
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High-risk patients 
 The following host factors contribute to more severe disease and its 
complications: 
• infants and the elderly, 
• obesity, 
• pregnant women, 
• peptic ulcer disease, 
• women who have menstruation or abnormal vaginal bleeding, 
• haemolytic diseases such as glucose-6-phosphatase dehydrogenase (G-
6PD) deficiency, 
• thalassemia and other haemoglobinopathies, 
• congenital heart disease, 
• chronic diseases such as diabetes mellitus, hypertension, asthma, 
ischaemic heart disease, 
• chronic renal failure, liver cirrhosis, 
• patients on steroid or NSAID treatment,  
Laboratory Diagnosis 
 Rapid and accurate dengue diagnosis is of paramount importance for: (i) 
epidemiological surveillance;(ii) clinical management; (iii) research; and (iv) 
vaccine trials.Clinical management requires early diagnosis of cases, 
confirmation of clinical diagnosis and for differential diagnosis from other 
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flaviviruses/infection agents.The following laboratory tests are available to 
diagnose dengue fever and DHF: 
  Virus isolation – serotypic/genotypic characterization 
  Viral nucleic acid detection 
  Viral antigen detection 
  Immunological response based tests – IgM and IgG antibody assays 
  Analysis for haematological parameters 
 Diagnostic tests and phases of disease 
 Dengue viraemia in a patient is short, typically occurs 2–3 days prior to 
the onset of fever and lasts for four to seven days of illness. During this period 
the dengue virus, its nucleic acid and circulating viral antigen can be detected 
Antibody response to infection comprises the appearance of different types of 
immunoglobulins and IgM and IgG immunoglobulin isotypes are of diagnostic 
value in dengue. IgM antibodies are detectable by days 3–5 after the onset of 
illness, rise quickly by about two weeks and decline to undetectable levels after 
2–3 months. IgG antibodies are detectable at low level by the end of the first 
week, increase subsequently and remain for a longer period (for many years). 
Because of the late appearance of IgM antibody, i.e. after five days of onset of 
fever, serological tests based on this antibody done during the first five days of 
clinical illness are usually negative. 
 During the secondary dengue infection (when the host has previously 
been infected by dengue virus), antibody titres rise rapidly. IgG antibodies are 
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detectable at high levels, even in the initial phase, and persist from several 
months to a lifelong period. IgM antibody levels are significantly lower in 
secondary infection cases. Hence, a ratio of IgM/IgG is commonly used to 
differentiate between primary and secondary dengue infections. 
Thrombocytopenia is usually observed between the third and eighth day of 
illness followed by other haematocrit changes.  
Isolation of virus 
 Isolation of dengue virus from clinical specimens is possible provided the 
sample is taken during the first six days of illness and processed without delay. 
Specimens that are suitable for virus isolation include: acute phase serum, 
plasma or washed buffy coat from the patient, autopsy tissues from fatal cases 
(especially liver, spleen, lymph nodes and thymus), and mosquitoes collected 
from the affected areas Currently, cell culture is the most widely used method 
for dengue virus isolation. The mosquito cell line C6/36 or AP61 are the host 
cells of choice for isolation of dengue viruses. 
Viral nucleic acid detection 
 Dengue viral genome, which consists of ribonucleic acid (RNA), can be 
detected by reverse transcripatse polymerase chain reaction (RT-PCR) assay.  
Nested RT-PCR 
 Nested RT-PCR assay involves using universal dengue primers targeting 
the C/prM region of the viral genome for an initial reverse transcription and 
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amplification step, followed by a nested PCR amplification that is serotype-
specific. 
One-step multiplex RT-PCR 
 This test is an alternative to nested RT-PCR. A combination of the four 
serotype - specific reactions are separated by electrophoresis on an agarose gel, 
and the amplification products are visualized as bands of different molecular 
weights after staining the gel using ethidium bromide dye, and compared with 
standard molecular weight markers. In this assay, dengue serotypes are 
identified by the size of their bands. 
Real-time RT-PCR 
 The real-time RT-PCR assay is also a one-step assay system using primer 
pairs and probes that are specific to each dengue serotype. The use of a 
fluorescent probe enables the detection of the reaction products in real time.The 
test is very useful for large-scale surveillance. 
Isothermal amplification method 
 The NASBA (nucleic acid sequence-based amplification) assay is an 
isothermal RNA-specific amplification assay that does not require thermal 
cycling instrumentation.  
         Compared with virus isolation, the sensitivity of the RT-PCR methods 
varies from 80% to 100% and depends upon the region of the genome targeted 
by the primers, the approach used to amplify or detect PCR products and the 
methods employed for subtyping. The advantages of this technology include 
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high sensitivity and specificity, ease of identifying serotypes and early detection 
of the infection. It is, however, an expensive technology. 
 Recently, Loop Mediated Amplification (LAMP) PCR method has been 
developed, which promises an easy-to-do and less expensive instrumentation 
alternative for RT-PCR and real-time PCR assays. 
Viral antigen detection 
 The NS1 gene product is a glycoprotein produced by all flaviviruses and 
is essential for replication and viability of the virus. The protein is secreted by 
mammalian cells but not by insect cells. NS1 antigen appears as early as Day 1 
after the onset of the fever and declines to undetectable levels by 5–6 days. 
Hence, tests based on this antigen can be used for early diagnosis.ELISA and 
dot blot assays directed against the envelop/membrane (EM) antigens and non-
structural protein 1 (NS1) demonstrated that this antigen is present in high 
concentrations in the sera of the dengue virus-infected patients during the early 
clinical phase of the disease  and can be detected in both patients with primary 
and secondary dengue infections for up to six days after the onset ofthe illness. 
Commercial kits for the detection of NS1 antigens are now available; however, 
these kits do not differentiate between the serotypes 
Immunological response and serological tests 
 Five basic serological tests are used for the diagnosis of dengue infection. 
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IgM-capture enzyme-linked immunosorbent assay (MAC-ELISA) 
 MAC-ELISA has become widely used in the past few years. It is a simple 
and rapid test that requires very little sophisticated equipment. MAC-ELISA is 
based on detecting the dengue-specific IgM antibodies in the test serum by 
capturing them out of solution using anti-human IgM that was previously bound 
to the solid phase35. If the patient’s serum has antidengue IgM antibody, it will 
bind the dengue antigen that is added in the next step and can be detected by 
subsequent addition of an enzyme-labelled anti-dengue antibody, which may be 
human or monoclonal antibody. An enzyme-substrate is added to produce a 
colour reaction. 
 The anti-dengue IgM antibody develops a little earlier than IgG, and is 
usually detectable by Day5 of the illness, i.e. the antibody is not usually 
detectable during the first five days of illness. However,the time of appearance 
of IgM antibody varies considerably among patients. IgM antibody titers in 
primary infections are significantly higher than in secondary infections, 
although it is not uncommon to obtain IgM titers of 320 in the latter cases. In 
some primary infections, detectable IgM may persist for more than 90 days, but 
in most patients it wanes to an undetectable level by 60 days MAC-ELISA is 
slightly less sensitive than the HI test for diagnosing dengue infection. MAC-
ELISA has become an invaluable tool for surveillance of DF, DHF and DSS.It 
is especially useful for hospitalized patients who are generally admitted at a late 
stage of illness after detectable IgM is already present in the blood. 
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IgG-ELISA 
 An indirect IgG-ELISA has been developed and compares well with the 
HI test.This test can also be used to differentiate primary and secondary dengue 
infection  
Interpretation of dengue diagnostic tests (adapted from Dengue and 
Control (DENCO) study 
 
IgM/IgG ratio 
 The IgM/IgG ratio is used to distinguish primary infection from 
secondary dengue infection . A dengue virus infection is defined as primary if 
the capture IgM/IgG ratio is greater than 1.2, or as secondary if the ratio is less 
than 1.2  
Haemagglutination inhibition test 
 Of the above tests, haemagglutination inhibition or HI test has been most 
frequently used in the past for routine serological diagnosis of dengue 
infections. It is sensitive and easy to perform, requires only minimal equipment 
HI antibodies persist for longperiods (up to 50 years or longer), the test is ideal 
for sero-epidemiologic studies 
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Complement fixation test 
 The complement fixation or CF test is not widely used for routine dengue 
diagnostic serology. It is more difficult to perform and requires highly trained 
personnel.  
Neutralization test 
 The neutralization test or NT is the most specific and sensitive 
serological test for dengue viruses used for determining the immune protection. 
The common protocol used in most dengue laboratories is the serum dilution 
plaque reduction neutralization test (PRNT)                                                                       
 Rapid diagnostic test (RDT) 
 A number of commercial rapid format serological test-kits for anti-
dengue IgM and IgG antibodies have become available in the past few years, 
some of these producing results within 15 minutes36.Unfortunately, the accuracy 
of most of these tests is uncertain since they have not yet been properly 
validated. Rapid tests can yield false positive results due to cross-reaction with 
other flaviviruses, malaria parasite, leptospires and immune disorders such as 
rheumatoid and lupus. 
Haematological tests 
 Standard haematological parameters such as platelet count and 
haematocrit are important and are part of the biological diagnosis of dengue 
infection. Therefore, they should be closely monitored. 
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 Thrombocytopenia, a drop in platelet count below 100 000 per μl, may be 
occasionally observed in dengue fever but is a constant feature in DHF. 
Thrombocytopenia is usually found between the third and eighth day of illness 
often before or simultaneously with changes in haematocrit. 
 Haemoconcentration with an increase in the haematocrit of 20% or more 
(for the same patient or for a patient of the same age and sex) is considered to 
be a definitive evidence of increased vascular permeability and plasma leakage. 
Basic metabolic panel findings include the following: 
 Hyponatremia is the most common electrolyte abnormality observed in 
patients with DHF or DSS.  
 Metabolic acidosis is observed in those with shock, and it must be 
corrected rapidly. 
 Elevated BUN is observed in those with shock. 
 Liver function test findings include the following: 
 Mild elevations in transaminase levels may be seen. 
 Low albumin is a sign of hemoconcentration 
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CASE DEFINITION2  
DENGUE FEVER:is defined by 
 
DENGUE HEMORRHAGIC FEVER: is defined by 
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DENGUE SHOCK SYNDROME:is defined by 
 
SEVERITY GRADING OF DENGUE: 
WHO classification of dengue infections and grading of severity of DHF 
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MANAGEMENT 
Disease notification 
 In dengue-endemic countries, cases of suspected, probable and confirmed 
dengue should be notified as soon as possible so that appropriate public health 
measures can be initiated . Laboratory confirmation is not necessary before 
notification, but should be obtained. In non-endemic countries, usually only 
confirmed cases will be notified. Suggested criteria for early notification of 
suspected cases are that the patient lives in or has travelled to a dengue-endemic 
area, has fever for three days or more, has low or decreasing white cell counts, 
and/or has thrombocytopenia ± positive tourniquet test. In dengue-endemic 
countries, the later the notification, the more difficult it is to prevent 
dengue transmission. 
Treatment of Dengue & DHF2: 
Febrile Phase: 
 In the initial phase the treatment of DF & DHF is the same and is as that 
of any other viral fever, i.e. symptomatic and supportive. 
  Rest. 
  Paracetamol (not > than 4 times in 24 hrs) according to age and 
weight for fever above 39°C. 
  Do not give Aspirin or Brufen. Aspirin can cause gastritis and/or 
bleeding. In children, Reye’s syndrome (Encephalopathy) may be a serious 
complication. 
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  Do not give antibiotics as these do not help. 
  Oral Rehydration Therapy is recommended as there may be mild to 
moderate Dehydration due to vomiting & high temperature. 
  Food can be given as per appetite. 
Dengue Hemorrhagic Fever 
 Patients with known or suspected DF should have their platelet count and 
Hematocrit measured daily from the third day of illness until 1-2 days after 
defervescence. Those patients with a rising hematocrit or falling platelet count 
should have intravascular volume deficits replaced. Those patients who improve 
can continue to be monitored in an outpatient setting. Those patients who do not 
improve should be admitted to the hospital for continued hydration. 
Other indications of Hospitalization include: 
 Patients who develop signs of Tachycardia 
 ↑ CRT ( > 2 sec) 
 Cool and clammy extremities 
 Diminished peripheral pulses 
 Changes in Mental status 
 Oliguria 
 Sudden rise in hematocrit 
 Narrowing of pulse pressure ( < 20 mm Hg ) 
 Hypotension ( Late finding-Uncorrected shock ) 
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 Intravascular volume deficits should be corrected with isotonic fluids 
such as Ringer lactate solution. Boluses of 10-20 ml/kg should be given over 20 
minutes and may be repeated. If this fails to correct the deficit, the hematocrit 
value should be determined, and, if it is rising, limited clinical information 
suggests that a plasma expander may be administered. Starch, dextran 40, or 
albumin 5% at a dose of 10-20 ml/kg may be used. If the patient does not 
improve after this, blood loss should be considered. Patients with internal or 
gastrointestinal bleeding may require transfusion. Patients with coagulopathy 
may require fresh frozen plasma. 
 After patients with dehydration are stabilized, they usually require 
intravenous fluids for no more than 24-48 hours. Intravenous fluids should be 
stopped when the hematocrit level falls below 40% and adequate intravascular 
volume is present. At this time, patients reabsorb extravasated fluid and are at 
risk for volume overload if intravenous fluids are continued. Do not interpret a 
falling hematocrit value in a clinically improving patient as a sign of internal 
bleeding. 
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Fluid therapy  
DENGUE GRADE 1,II 
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DENGUE GRADE III,IV 
UNSTABLE VITALS  
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Fluids Recommended: 
Crystalloids : 
 5% Dextrose in Isotonic NS 
 5% Dextrose in 1/2 NS 
 5% Dextrose in RL 
 Shock Correction NS or RL 
Colloids : 
 Dextran 40 
 Hemaccel 
 Plasma 
Fluid Replacement 
 Volume of fluid to be just sufficient to maintain effective circulation 
during plasma leakage. 
 Fluid charts to be made every 1 to 3 hrs and even more frequently in 
shock. 
 Change should not be drastic. e.g. don’t jump from 20 ml to 6ml or vice 
versa. Go in a step wise manner. 
Indications of Platelet / Whole blood transfusion2 
Platelets 
 Platelet count < 20,000/ cu.mm 
 Platelet count >20,000 <40,000 with hemorrhagic manifestations. 
 DIC 
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Whole Blood 
 Prolonged refractory shock with ↓↓HCT even with adequate fluid 
replacement 
 Severe massive bleeding ( > 10 % of total blood volume). 
Indications of FFP 
(Fresh frozen Plasma) 
 Plasma is used when HCT is rising despite fluid replacement 
 But plasma substitutes are equally good (Dextran 40) & effective 
 Essential only in cases of massive bleeding with DIC. 
Monitoring of patients in DSS 
 Check vitals every 15-30 minutes until shock is overcome. 
 Check HCT / Platelets for every 2 hours for the first 6 hours and every 4 
hours until stable. 
 Fluid balance sheet to be maintained. Frequency & volume of urine 
output to be recorded. In refractory shock catheter may be needed. 
Criteria for Discharge2 
 Patients who are resuscitated from shock recover rapidly. Patients with 
DHF or dengue shock syndrome (DSS) may be discharged from the hospital 
when they meet the following criteria: 
 Afebrile for 24 hours without antipyretics 
 Good appetite, clinically improved condition 
 Adequate urine output 
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 Stable hematocrit 
 At least 48 hours have passed since recovery from shock 
 Absence of respiratory distress 
  Platelet count greater than 50,000. 
Management of high-risk patients 
 Obese patients have less respiratory reserves and care should be taken to 
avoid excessive intravenous fluid infusions. The ideal body weight should 
be used to calculate fluid resuscitation and replacement and colloids 
should be considered in the early stages of fluid therapy. Once stabilized, 
furosemide may be given to induce diuresis. 
 Infants also have less respiratory reserves and are more susceptible to 
liver impairment and electrolyte imbalance. They may have a shorter 
duration of plasma leakage and usually respond quickly to fluid 
resuscitation. Infants should, therefore, be evaluated more frequently for 
oral fluid intake and urine output. 
 Intravenous insulin is usually required to control the blood sugar levels in 
dengue patients with diabetes mellitus. Non-glucose containing 
crystalloids should be used. 
 Patients with hypertension may be on anti-hypertensive therapy that 
masks the cardiovascular response in shock. The patient’s own baseline 
blood pressure should be considered. A blood pressure that is perceived 
to be normal may in fact be low for these patients. 
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 Anti-coagulant therapy may have to be stopped temporarily during the 
critical period. 
 Haemolytic diseases and haemoglobiopathies : These patients are at risk 
of haemolysis and will require blood transfusion. Caution should 
accompany hyper hydration and alkalinisation therapy, which can cause 
fluid overload and hypo calcemia. 
• Congenital and ischemic heart diseases: Fluid therapy should be more 
cautious as they may have less cardiac reserves. 
 For patients on steroid therapy, continued steroid treatment is 
recommended but the route may be changed. 
Management of complications 
The most common complication is fluid overload 
Detection of fluid overload in patients 
 Early signs and symptoms include puffy eyelids, distended abdomen 
(ascites), tachypnoea, mild dyspnoea. 
 Late signs and symptoms include all of the above, along with moderate to 
severe respiratory distress, shortness of breath and wheezing (not due to 
asthma) which are also an early sign of interstitial pulmonary oedema and 
crepitations. Restlessness/agitation and confusion are signs of hypoxia 
and impending respiratory failure. 
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Management of fluid overload 
  All hypotonic solutions should be stopped. In the early stage of fluid 
overload, switch from crystalloid to colloid solutions as bolus fluids. Dextran 40 
is effective as 10 ml/kg bolus infusions, but the dose is restricted to 30 
ml/kg/day because of its renal effects. Dextran 40 is excreted in the urine and 
will affect urine osmolarity. Patients may experience “sticky” urine because of 
the hyperoncotic nature of Dextran 40 molecules (osmolarity about twice that of 
plasma). Voluven may be effective (osmolarity = 308 mosmole) and the upper 
limit is 50ml/kg/day. However, no studies have been done to prove its 
effectiveness in cases of DHF/DSS. In the late stage of fluid overload or those 
with frank pulmonary oedema, furosemide may be administered if the patient 
has stable vital signs. If they are in shock, together with fluid overload 10 
ml/kg/h of colloid (dextran) should be given. When the blood pressure is stable, 
usually within 10 to 30 minutes of infusion, administer IV 1 mg/kg/dose of 
furosemide and continue with dextran infusion until completion. Intravenous 
fluid should be reduced to as low as 1 ml/kg/h until discontinuation when 
haematocrit decreases to baseline or below (with clinical improvement). The 
following pointsshould be noted: 
 These patients should have a urinary bladder catheter to monitor hourly 
urine output. 
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 Furosemide should be administered during dextran infusion because the 
hyperoncotic nature of dextran will maintain the intravascular volume 
while furosemide depletes in the intravascular compartment. 
 After administration of furosemide, the vital signs should be 
monitored every 15 minutes for one hour to note its effects. 
 If there is no urine output in response to furosemide, check the 
intravascular volume status (CVP or lactate). If this is adequate, pre-renal 
failure is excluded, implying that the patient is in an acute renal failure 
state. These patients may require ventilatory support soon.. 
 In cases with no response to furosemide (no urine obtained), repeated 
doses of furosemide and doubling of the dose are recommended. If 
oliguric renal failure is established, renal replacement therapy is to be 
done as soon as possible. These cases have poor prognosis. 
 Pleural and/or abdominal tapping may be indicated and can be life-saving 
in cases with severe respiratory distress and failure of the above 
management. This has to be done with extreme caution because traumatic 
bleeding is the most serious complication and leads to death.  
Management of encephalopathy 
 Some DF/DHF patients present unusual manifestations with signs and 
symptoms of central nervous system (CNS) involvement, such as convulsion 
and/or coma. This has generally been shown to be encephalopathy, not 
encephalitis, which may be a result of intracranial haemorrhage or occlusion 
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associated with DIC or hyponatremia. CNS infections documented by virus 
isolations from the cerebrospinal fluid (CSF) or brain. 
Most of the patients with encephalopathy report hepatic encephalopathy. The 
principal treatment of hepatic encephalopathy is to prevent the increase of 
intracranial pressure (ICP).Radiological imaging of the brain (CT scan or MRI) 
is recommended if available to rule out intracranial haemorrhage. The following 
are recommendations for supportive therapy for this condition: 
 Maintain adequate oxygenation with oxygen therapy. Prevent/reduce ICP 
by the following measures: 
o give minimal IV fluid to maintain adequate intravascular volume; 
ideally the total IV fluid should not be >80% fluid maintenance. 
o switch to colloidal solution earlier if haematocrit continues to rise 
and a large volume of IV is needed in cases with severe plasma 
leakage. 
o administer a diuretic if indicated in cases with signs and symptoms 
of fluid overload. 
o positioning of the patient must be with the head up by 30 degrees. 
o early intubation to avoid hypercarbia and to protect the airway. 
o may consider steroid to reduce ICP. Dexamethazone 0.15 
mg/kg/dose IV to be administered every 6–8 hours. 
 Decrease ammonia production by the following measures: 
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o give lactulose 5–10 ml every six hours for induction of osmotic 
diarrhoea. 
o local antibiotic gets rid of bowel flora; it is not necessary if 
systemic antibiotics are given. 
 Maintain blood sugar level at 80–100 mg/dl per cent. Recommend 
glucose infusion rate is anywhere between 4–6 mg/kg/hour. 
 Correct acid-base and electrolyte imbalance, e.g. correct 
hypo/hypernatremia, hypo/hyperkalemia, hypocalcemia and acidosis. 
 Vitamin K1 IV administration; 3 mg for <1-year-old, 5 mg for <5-year-
old and 10 mg for>5-year-old and adult patients. 
 Anticonvulsants should be given for control of seizures: phenobarbital, 
dilantin and diazepam IV as indicated. 
 Transfuse blood, preferably freshly packed red cells, as indicated. Other 
blood components such as as platelets and fresh frozen plasma may not 
be given because the fluid overload may cause increased ICP. 
 Empiric antibiotic therapy may be indicated if there are suspected 
superimposed bacterial infections. 
 H2-blockers or proton pump inhibitor may be given to alleviate 
gastrointestinal bleeding. 
 Avoid unnecessary drugs because most drugs have to be metabolized by 
the liver. 
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 Consider plasmapheresis or haemodialysis or renal replacement therapy 
in cases with clinical deterioration. 
VECTOR CONTROL 
 Environmental management methods37 
 Environmental modification: This includes any long-lasting physical 
transformation of land, water and vegetation aimed at reducing vector 
habitats without causing unduly adverse effects on the quality of the 
human environment. 
 Environmental manipulation: This incorporates planned recurrent 
activities aimed at producing temporary changes in vector habitats that 
involve the management of “essential” and “non-essential” containers, 
and the management or removal of “natural” breeding sites.such as 
1. improved water supply 
2. covering of overhead tanks  
3. land filling, levelling  
 Changes to human habitation or behaviour: These feature the efforts 
made to reduce man-vector-virus contact. 
Biological control 
 Biological control is based on the introduction of organisms that prey 
upon, reduce populations of the target species. The application of biological 
control agents, which are directed against the larval stages of dengue vectors, 
While biological control avoids chemical contamination of the environment, 
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Larvivorus fish (Gambusia affinis and Poecilia reticulata) have been 
extensively used for the control of An. stephensi and/or Ae. aegypti in large 
water bodies or large water containers in many countries. Two species of 
endotoxin-producing bacteria, Bacillus thuringiensis serotype H-14  and 
Bacillus sphaericus  are effective mosquito control agents. Copepods have a 
role in dengue vector control, 
Chemical control 
 Chemicals have been used to control Ae. aegypti since the beginning of 
the 20th century. Aedes larval habitats were treated with oil and homes were 
fumigated with pyrethrins DDT emerged in the early 1960s, organophosphate 
insecticides, including fenthion, malathion and fenitrothion, were used for Ae. 
aegypti adult control and temephos as a larvicide. Current methods are larvicide 
application and space spraying. Larviciding or “focal” control of Ae. aegypti is 
usually limited to domestic-use containers that cannot be destroyed, eliminated 
or otherwise managed. It is difficult and expensive to apply chemical larvicides 
on a long-term basis. Therefore, chemical larvicides are best used in situations 
where the disease and vector surveillance indicate the existence of certain 
periods of high risk and in localities where outbreaks might occur 
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Personal protection 
Protective clothing 
 Clothing reduces the risk of mosquito bite if the cloth material is 
sufficiently thick or loosely fitting. Long sleeves and trousers with stockings 
may protect the arms and legs, which are the preferred sites for mosquito bites. 
Schoolchildren should adhere to these practices whenever possible Household 
insecticidal products, namely mosquito coils and aerosols, are used extensively 
for personal protection against mosquitoes. Repellents are common means of 
personal protection against mosquitoes and other biting insects .Insecticide-
treated mosquito nets (ITNs) have limited utility in dengue control programmes 
since the vector species bites during the day. 
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METHODOLOGY 
Type of Study: Cross Sectional Study.  
Study Period: The study was conducted from Dec 2009 to Dec 2010.  
Settings: Children less than 12 years of age with clinical features of Dengue 
(any acute febrile illness with two of the following: myalgia, head ache, retro-
orbital pain, bleeding, altered sensorium, shock or low platelet count) admitted 
at Children Medical Ward of Tirunelveli Medical College Hospital during the 
study period were registered in the study. Informed consent was obtained and 
detailed history was taken. For all cases, the rapid Ig M ELISA test was done at 
our hospital. Children positive for Ig M were followed up for clinical profile. 
Sample Size: From Dec 2009 to Dec 2010, there were totally 53 cases 
according to the inclusion and exclusion criteria.   
 Inclusion Criteria:  
• Children less than 12 years of age with clinical features of dengue (any 
acute febrile illness) with two of the following : 
o Rash 
o Headache 
o Myalgia/ Arthralgia 
o Bleeding manifestation 
o Altered sensorium 
o Retro orbital pain 
o Shock or low platelet count 
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Exclusion Criteria: 
• Clinical Features suggestive of Dengue with other serology positive 
cases.  
Tools used:  
Using Proforma the basic socio demographic details, Clinical features were 
collected. Laboratory investigations carried out in these patients include 
Haemoglobin, Complete blood count, Dengue IgM serology, Liver function 
test, serum amylase. Chest X ray was taken to demonstrate pleural effusion. 
Ultrasound abdomen was done to identify ascites, polyserositis and gall bladder 
wall thickening. CSF analysis was done in patients with convulsions, meningeal 
signs and altered sensorium. 
Outcome Measures:  Children positive for IgM were followed for the clinical 
profile and outcome.  
The number of children included based on the above criteria was 53. Children 
who were seropositive were classified on the basis of WHO criteria as follows: 
1. Dengue fever (DF): dengue seropositive without bleed. 
2. Dengue fever with unusual bleed (DFB): dengue seropositive with 
bleeding tendencies, not satisfying WHO criteria for DHF 
3. Dengue haemorrhagic fever (DHF): Dengue seropositive with bleeds with 
evidence of plasma leakage. 
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4. Dengue Shock Syndrome (DSS): DHF with evidence of peripheral 
circulatory failure. 
Data Analysis: 
Data collected were entered in Excel Spreadsheet and analysed using SPSS 
Version 16. Simple calculations like Percentages, Proportions and Mean values 
were derived. Appropriate statistical tests like Chi – Square test, T test were 
used.                           
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OBSERVATION &RESULTS 
 53 sero positive dengue cases were reported  in our hospital during study 
period. 
 Dengue fever:11(20.8%) 
 Dengue hemorrhagic fever:29 (54.7%) 
 Dengue shock syndrome:13(24.5%) 
TABLE 1 
CLINICAL FEATURES: 
NO FEATURES TOTAL 
(n=53) 
DF(n=11) DHF(n=29) DSS(n=13) P 
value 
1 Mean 
Age(yr)(±SD) 
6.6(±3.8) 6.05(±4.2) 7.0(±3.4) 6.4(±4.5) 0.35 
2 Age yrs <1 
year  
9(17%) 2(18.2%) 3(10.3%) 4(30.8%)   
3 Age 1-5 years 11(20.8%) 4(36.4%) 6(20.7%) 1(7.7%) 
4 Age 6-12 
years 
33(62.3%) 5(45.4%) 20(69%) 8(61.5%) 
5 Mean duration 
of fever (±SD)
6.02(±2.7) 6.18(±3.7) 6.21(±2.3) 5.46(±3.01) 
6 Female sex 
no.,% 
27(50.9%) 6(54.5%) 15(51.7%) 6(46.2%) 
 
 The age group of the affected children were between 6 months to 12 
years.( Mean 6.6 yrs ,standard deviation 3.8 ). Infants comprised 17% of total 
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study group. 20.8% were children between 1 and 5 years of age. 62.3% were 
children between 6 and 12 years.DHF and DSS was found to be more common 
in 6-12 years age group. But this fact is not statistically significant. Mean 
duration of fever was 6.02 days. It was 6.18,6.21,5.46 days in DF, , DHF, DSS 
respectively. Males(49.1%) and females(50.9%) were comparatively equally 
affected. 
TABLE 2 
CLINICAL FEATURES 
No Features TOTAL 
(n=53) 
DF 
(n=11) 
DHF 
(n=29) 
DSS 
(n=13) 
P 
VALUE 
1 ABDOMINAL 
PAIN 
22(41.5%) 2(18.2%) 18(62.1%) 2(15.4%) 0.004 
2 VOMITING 36(67.9%) 8(72.7%) 20(69%) 8(61.5%) 0.82 
3 DIARRHOEA 10(18.9%) 2(18.2%) 1(3.4%) 7(53.8%) 0.001 
4 SEIZURE 6(11.3%) 1(9.1%) 0 5(38.5%) 0.001 
5 COUGH 14(26.4%) 1(9.1%) 9(31%) 4(30.8%) 0.342 
 
 Most common symptoms were fever 100%, vomiting 67.9% and 
Abdominal pain 41.5%. Fever was present in all children. Abdominal pain was 
common in DHF (62.1%) when compared to DF (18.2%) and DSS (15.4).It is 
statistically significant P=0.004.Diarrhoea was more common in DSS (53.8%) 
compared to DF and DHF. It is statistically significant. SEIZURE was common 
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in  DSS(38.5%) while none of the DHF cases had seizure. Both are statistically 
significant. 
TABLE 3 
CLINICAL FEATURES 
 
 GI bleed was present  in 34% of the patients. GI bleed was significantly 
higher in DSS.HESS test was positive in more DSS cases than DHF.But this is 
not statistically significant. 
                             
 
 
 
 
 
 
No Features TOTAL(n=53) DF(n=11) DHF(n=29) DSS(n=13) P 
VALUE
1  Rash 20(37.7%) 4(36.4%) 11(37.9%) 5(38.5%) 0.9 
2 GI BLEED  18(34%) 0 11(37.9%) 7(53.8%) 0.017 
3 POSITIVE 
HESSTEST 
10(18.9%) 0 6(20.7%) 4(30.8%) 0.148 
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TABLE 4 
HEMATOLOGICAL  VALUE 
No Features TOTAL 
(n=53) 
DF 
(n=11) 
DHF 
(n=29) 
DSS 
(n=13) 
P 
VALUE 
1 PLATELET 
COUNT 
mean(SD) 
70132 
(±53684) 
89636 
(±55352) 
71206 
(±59996) 
51230 
(±28249
) 
0.2 
2 PCV 
mean(SD) 
38.30 
(±6.10) 
36.16 
(±4.95) 
39.84 
(±6.54) 
36.69 
(±5.35) 
0.12 
 
 
 
 
 The mean platelet count was 70132.DSS cases had a lower count than the 
mean. but it is not statistically significant . Mean hematocrit value was 
comparatively higher in DHF. But it was not statistacally significant. 
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TABLE 4 
PLATELET COUNT (Per cu mm) 
NO PLATELET 
COUNT 
TOTAL 
(n=53) 
DF 
(n=11) 
DHF 
(n=29) 
DSS 
(n=13) 
P 
1 <20000 2(3.8%) 0 1(3.4%) 1(7.7%) 0.21
 
2 20000-50000 21(39.6%) 3(27.3%) 13(44.8%) 5(38.5%)  
3 50001-100000 20(37.7%) 6(54.5%) 7(24.1%) 7(53.8%)  
4 >100000 10(18.9%) 2(18.2%) 8(27.6%) 0  
 
 Most patients had a platelet count between 20,000-50,000(39.6%).While 
DHF patients commonly had counts less than 50,000 ,the counts were more than 
50,000 in 53.8% of DSS cases. But this is not statistically significant. 
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DISCUSSION 
              As discussed in the literature, SouthEastAsian region has a varied 
clinical profile and outcome compared to the rest of the world. The 
demographic pattern and the trend of illness are vastly changing every year 
through the past decade. South India and especially SouthTamilnadu has 
witnessed several dengue epidemic outbreaks during the past few years. Here I 
compare the clinical profile and outcome of Dengue in our hospital with other 
Indian and  study done other countries.  
            Totally 53 Sero-positive cases dengue children who presented at 
Tirunelveli Medical College hospital during the study period were analysed. As 
per the WHO classification, the frequency of Dengue fever was 20.8%, Dengue 
hemorrhagic fever 54.7% and Dengue shock syndrome 24.5%, while no cases 
presented Dengue fever having unusual bleed.(i.e. bleeding without plasma 
leakage) Narayanan et al (Chennai2001)reported DF (72.78%), DHF (18.6%), 
DSS (8.4%).  Kalyanarooj et al (Indonesia) reported DF (including DFB) 
(53%), DHF (including DSS)(47%). Ratageri et al(Hubli2003) reported 
DF(18%),DHF (includingDSS) is 82%. In present study, DHF (including DSS) 
is 79.2%. Present study is comparable with other studies. 
 This shows that severe forms of dengue-DHF and DSS have increased 
over the decade. It may be due to increasing endemicity, environmental factors 
and changing virulence of the viruses.                                                                                   
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           Baseline microvascular permeability in children is greater than that of 
adults and this could partly explain why DHF and DSS are more frequently seen 
in children38. 
AGE:  
 In the present study Dengue infection was noted in 17% of infants , 1-
5yrs(20.8%)and  62.3% of children 6-12yrs  was observed. Manjunath J. 
Kulkarni et al Clinico-Epidemiological Profile of Children Hospitalized with 
Dengue  Indian J Pediatr (2010) 77:1103–1104  study shows Children in 6–12 
yrs age group constituted 45.8% of cases forming the most commonly affected 
group.  Fahad Javaid Siddiqui et al.  Study shows older children appeared 5.5 
times more likely to be affected than their younger  (0 – 5 years) counterparts. 
These are comparable with our present study. 
SEX:      
 In the present study, there is no sex predilection for the disease (male 
49.1% compared to female 50.1%), while both sexes had equal distribution of 
disease severity. Regarding the relationship between gender and severity among 
children, Nimmannitya(1987a,b) reported that shock and death occurred more 
frequently in females than in males.  (Garcia-Rivera et al, 2003;. studies 
reporting no significant difference in frequency between male and female. 
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FEVER: 
              In the present study all children had fever. Mean duration  fever was 
6.02 days. In DSS mean duration of fever was 5.14 days. Chandrakanta,et al 
study shows mean duration of fever 10.7%. 
VOMITING: 
 In the present study  67.9% children had vomiting. Manjunath J. Kulkarni  
et al reported vomiting in 35.2% children.Chandrakanta,et  al (Changing clinical 
manifestations of dengue infection in north India dengue bulletin 2008)shows  
vomiting was  41.2%.  Ratagiri et al  study shows  82%.The percentage is 
variable in different studies. 
ABDOMINAL PAIN: 
 In the present study 41.5% children had abdominal pain. Chandrakanta,et 
al study shows 25%.Shigeki Hanafusa  et al study shows 68%.In the present 
study abdominal pain  was significantly more common in DHF (62.1%). 
GI BLEEDING: 
 The present study shows 34% incidence of GI bleeding. Chandrakanta,et 
al shows 38.8%. Narayanan et al shows high percentage 61% of hematemesis. 
In the present study GI bleeding was significantly more common in DSS.  
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SHOCK 
No Study % 
1 Aggarwal et al 33 
2 Gomber et al 20 
3 Narayanan et al 8.4 
4 Kabilan et al 23.8 
5 Ratagiri et al 22 
6 Present study 24.5 
 
 DSS was low in Narayanan et al. Due to increasing endemicity and 
changing epidemiology, DSS is in increasing trend. 
RASH:  
 Chandrakanta, et al study shows 37.5% cases had skin rash. Shigeki 
Hanafusa1,2.et al  SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH 
Vol 39 No. 2 March 2008 study shows 55.1%. In the present study shows 
37.7% of skin rash. It is comparable with other studies. 
TOURNIQUET TEST: 
 In the Present study shows 18.9% positivity. Shigeki Hanafusa (Japan) et 
al study shows 85.7%tourniquet test positive. 23.7% in Narayanan and 52% in 
Kalyanarooj (Indonesia).The low percentage in our study(similar to another 
Indian study narayanan et al)compared to foreign studies may be due to 
difference in skin complexion and capillary fragility in Indian children. 
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DIARRHOEA: 
 Chandrakanta, et al study shows 6.2% of children had loose stools. In the 
present study  18.9% children had diarrhea and is statistically significantly 
reported  in DSS cases .This may be due to the poor socio economic status and 
nutritional status in our children,predisposing to early shock in dengue. 
SEIZURE: 
 Chandrakanta et al study shows  45% cases had seizure. In  present study 
11.3% cases had seizure.Most of the seizure occurred in DSS 38.5% . 
COUGH: 
 Shigeki Hanafusa et al study shows 35.4% children had cough. 
Manjunath J. Kulkarni  study shows 9.07% . In  the present study 26.4% of 
children had cough. Cough is a Unique feature of paediatric dengue compared 
to adult dengue. 
MEAN HEMATOCRIT: 
 Chandrakanta, et al study shows mean hematocrit value 26.8 %. 
Narayanan et al study shows 33.2%. Karthis et al study shows 34.06%. In the 
present study, mean hematocrit value is 38.30%. 
PLATELET COUNT: 
 In present study platelet count is as follows 
  <20000=3.8%               
  20000-50000=39.6% 
  50001-100000=37.7% 
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  >100000  =18.9% 
 Maimoona M. Ahmed J Infect Dev Ctries 2010; 4(8):503-510.study 
showed 
  <20000=6.75% 
  20000-50000=50% 
  50001-10000=41% 
  >100000=18.5% 
Present study is comparable with this study. 
 In the present study, there is no correlation between the counts and the 
disease severity with 48.2% of DHF occurring in children with counts less than 
50,000 while 53.8% of DSS in children with counts  more than 50,000.this is 
because in dengue, the Development of antibodies potentially cross-reactive to 
plasminogen could have a role in causing haemorrhage 39 . The increased 
destruction or decreased production of platelets could result in 
thrombocytopenia.count may thus not necessarily correlate to bleeding or 
disease severity. 
SGOT&SGPT: 
       Maimoona M. Ahmed study shows elevated liver enzyme value. Sharma 
et al. from India40 reported elevated transaminases in 90% of patients In the 
present  Study SGOT is elevated in 90.6% of the cases. SGPT is elevated in 
86.8% of the cases. In the present study serum Amylase level elevated .It was   
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72.7%,65.5%,69.2% in DF,DHF,DSS respectively. But it was statistically not 
significant.  
USG ABDOMEN: 
       Srikiatkhachom(Indonesia) study shows hepatomegaly 56% . Venkatasai 
study also had 21% of hepatomegaly. In present study there was hepatomegaly 
37.7% of patient .It was statistically significant. 
 The present study shows statistically significant right side pleural 
effusion and ascites, which is consistent with the pathophysiology of the plasma 
leakage in dengue. 
MORTALITY 
     Kabra et al study shows  12-13% of mortality.Agarwal et al study shows 
6% of  death .4.8% of mortality in gomberstudy. The present study shows 3.8% 
of  mortality which is consistent with the WHO observed case fatality rates in 
india(3-5%).The higher rates could be due to the higher rural population that 
reports to our institution.                             
 
 
 
 
 
 
 
68 
 
LIMITATIONS OF THE STUDY 
1. Confirmation of dengue viral infection was not done. So, all the cases in 
the study are PROBABLE DENGUE according to WHO case definition. 
2. Viral antibody titers were not done to diagnose primary and secondary 
dengue precisely .Only qualitative  IgM  was done .quantitative analysis 
and IgG titre analysis could not be done. 
3. Serotypes were not done. So the predominant serotype was not identified. 
4. Treatment modalities like type of fluid used, need for inotrope support, 
ventilator support, need for blood products were not studied. 
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CONCLUSION 
1. Dengue fever is becoming more prevalent in India, especially south India. 
Incidence of Dengue shock syndrome is increasing. 
2. Children between 6 and 12 yrs were most affected by dengue in my 
study. 
3. There was no sex predilection. 
4. Abdominal pain is a significant symptom in children with bleed(DHF).it 
is not a symptom to be ignored .Abdominal Pain in a child with suspected 
dengue should alert us to the possibility of GI bleed. 
5. Cases initially diagnosed as acute watery diarrhoea, eventually turned out 
to be dengue. And diarrhoea children with suspected dengue were 
significantly prone for DSS. Hence, high index of suspicion and 
aggressive management are the need in such cases. 
6. Seizure was significant in DSS cases. Any dengue child throwing 
convulsions should hence be promptly evaluated for unrecognised shock. 
7. The bleeding in dengue is not purely due to thrombocytopenia. It is due to 
multiple etiologies including vascular changes. Refraining from treating 
the platelet numbers rather than the patient and strict adherence to 
protocols would go a long way in preventing iatrogenic complications 
like fluid overload.  
8. There is no role for prophylactic platelet transfusion. 
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9. Children who presented to our setup with bleed  significantly progressed 
to DSS. It is thus an alarming sign. 
10. Early recognition, precise assessment and appropriate treatment as per 
established WHO protocols should reduce the high mortality rates. 
11. There is a probable need for region specific guidelines for better 
outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA FOR DENGUE FEVER 
  
Name  :    I.P.No:      Age / Sex :   
Blood group :  
Address :       Ad. on   Discharge  
Fever :   Type  
   Duration  
   Ass.with chills and rigor  
Previous Antibiotic Therapy & Duration  
Cough / Rhinitis :  
Vomiting :  
Hemetemesis  
Malena  
Hematuria 
Diarrhoea  
Abdominal pain 
Breathing Difficulty : Headache / Eye pain / back pain. Myalgia / Arthralgia / 
Neck pain. Facial puffiness / Eyelid edema /Throat pain / Ab. distension / 
Altered sensoriam / Irritable cry / Refusal of feeding  
Maculo papularash  / Petechial  
Seizure  
 
 
 
General Examination  
Periphries Cold / Warm    PR  RR  Temp  
Febrile / Afebrile    
Palar / Ictrus     Hess test :   BP  
Lymphadenopathy 
Pedal edema  
Cyanosis  
CVS     RS    P/A   
CNS  
INVESTIGATION 
Blood   Urea       LFT  
 Sugar      SGOT  
 Creatinine      SGPT 
 Na +       T. Protein  
 K +       Albumin  
     Sr. Amylase  
CBC  
 TC    DC    Hb    ESR   
Date       
Platelet      
PCV       
 
 
 
Peripheral smear  
X – ray chest  
USG Abdomen  
Dengue Serology with date  
WIDAL 
Urine  Albumin      PT  
  Sugar 
  Deposit      APTT  
Transfusion   
Treatment  
Outcome:     cured/expired                              
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S.NO AGE SEX BL.GP BL.TYP PLACE DOA DOD F. TYPE F. DAYS F. CHILLS COUGH VOMITING HEMETEMESIS MALENA DIARHOEA ABD.PAIN OTHERS
1 10M M B P KADAYAM                03.01.10 12.01.10 LOW 10 NO NO     NO                NO        NO        NO                NO    NO                             
2 10 F AB P KADAYAM                05.01.10 14.01.10 HIGH 4 NO NO     2episode          NO        NO        NO                NO    NO                             
3 9 F B P KOVILPATTI             10.01.10 15.01.10 LOW 7 NO 4 DAYS NO                NO        NO        NO                NO    NO                             
4 10 M B P KADAYAM                02.01.10 10.01.10 LOW 8 NO NO     2episode          NO        1 episode NO                NO    NO                             
5 1 F B N VEERAVANALLUR          11.01.10 17.01.10 LOW 5 NO NO     NO                1episode  NO        NO                NO    NO                             
6 10 F A P PETTAI                 03.01.10 08.01.10 LOW 4 NO NO     2episode          2episode  NO        NO                NO    breathing difficulty           
7 8 M B P KOVILPATTI             12.01.10 17.01.10 LOW 4 NO NO     2episode/day 2days 1episode  1 episode NO                NO    NO                             
8 10 F B P KOVILPATTI             11.01.10 16.01.10 LOW 5 NO NO     2episode/day 2days NO        NO        NO                3 DAYS ab distension                  
9 7 F B P KOVILPATTI             12.01.10 16.01.10 HIGH 5 NO NO     3-4episode/day    NO        NO        NO                2 DAYS NO                             
10 8 F A P SIVAGIRI               11.01.10 16.01.10 HIGH 4 NO NO     3-4episode/day    NO        1 episode NO                NO    NO                             
11 9 M B P KOVILPATTI             15.01.10 21.01.10 HIGH 5 NO NO     2episode/day 2days NO        NO        NO                NO    NO                             
12 7 M O P KADAYAM                10.01.10 15.01.10 HIGH 5 NO NO     2episode/day 1day NO        1 episode NO                NO    NO                             
14 11M M O P KADAYAM                14.01.10 18.01.10 LOW 7 NO NO     NO                NO        NO        NO                NO    NO                             
15 11 F O P KADAYAM                10.01.10 21.01.10 LOW 7 NO NO     3episode/day      NO        1 episode NO                NO    NO                             
16 9 M B P KADAYAM                15.01.10 21.01.10 LOW 5 NO NO     3episode/day      NO        NO        NO                NO    NO                             
17 12 F B P KADAYAM                21.01.10 25.01.10 HIGH 5 NO NO     7episode/day-4day NO        NO        NO                4 DAYS NO                             
18 12 M B P KOVILPATTI             21.01.10 26.01.10 HIGH 4 NO NO     5episode/day      2episode  1 episode 4-5episode/day    NO    1epistaxis                     
19 8M F B P KADAYAM                17.01.10 21.01.10 HIGH 8 NO 2 DAYS NO                NO        NO        NO                NO    breathing difficulty           
20 4 F B P KADAYAM                21.01.10 27.01.10 HIGH 2 NO NO     3episode/day      NO        NO        5-6episode/day    NO    NO                             
21 8 F B P KADAYAM                23.01.10 29.01.10 LOW 3 NO NO     2-3episode        NO        NO        NO                1 DAY NO                             
22 3 M B P KOVILPATTI             26.01.10 02.02.10 LOW 2 NO NO     3-4episode/day    NO        NO        NO                NO    NO                             
23 8 M B P TIRUNELVELI            20.12.09 30.12.09 HIGH 14 NO 10 DAYS NO                3-4episode 3 episodeS 5-6episode/day    6 DAYS Alteredsensorium               
24 9 F O P KOVILPATTI             14.12.09 18.12.09 LOW 7 NO NO     3-4episode/day    NO        NO        5-6episode/day    NO    NO                             
25 10 M B P SANKARANKOIL           23.12.09 29.12.09 INTERM 6 NO 7 DAYS 2-3episode        NO        NO        NO                2 DAYS NO                             
26 6 M A N VK PUTHUR              21.12.09 25.12.09 HIGH 6 NO NO     3-4episode/day    2episode  1 episode NO                NO    NO                             
27 8 M O P MARUTHAIPUTHUR         15.12.09 23.12.09 HIGH 7 NO NO     3-4episode/day    NO        NO        NO                2 DAYS NO                             
28 7M M O P THERKUPATTAI           19.12.09 31.12.09 HIGH 4 NO NO     2days             NO        NO        2 days            NO    NO                             
29 11M M O P TENKASI                24.12.09 29.12.09 INTERM 5 NO 4 DAYS 3episodes         NO        NO        NO                2 DAYS NO                             
30 8M M O P TIRUNELVELI            15.12.09 23.12.09 HIGH 7 NO NO     4episodes/4days   NO        NO        NO                2 DAYS NO                             
31 12 F B P TIRUNELVELI            19.01.10 26.01.10 INTERM 7 NO NO     4episodes/4days   NO        NO        NO                NO    dehydration                    
32 11 F A P TIRUNELVELI            21.01.10 27.01.10 HIGH 6 YES NO     2episodes         NO        NO        2 days            NO    NO                             
33 9M F O P KADAYAM                25.01.10 28.01.10 HIGH 7 NO NO     2episodes         NO        NO        NO                NO    NO                             
34 12 M O P KADAYAM                21.01.10 26.01.10 HIGH 4 NO NO     4episodes/4days   1episode  1 episode 4-5episode/day    NO    NO                             
35 8M F B P SANKARANKOIL           17.01.10 21.01.10 HIGH 4 NO NO     NO                NO        NO        NO                NO    dyspnoec,tachypnoec            
36 8 F A P THALYUTHU              03.01.10 08.01.10 HIGH 4 NO NO     NO                2episodes NO        1 day             NO    NO                             
37 10 F O P TIRUNELVELI            03.01.10 09.01.10 HIGH 3 NO 3 DAYS 3episodes         NO        NO        4 episodes        4 DAYS NO                             
38 3 M B P AMBAI                  11.12.09 25.12.09 INTERM 7 NO 7 DAYS 3episodes/2days   NO        NO        NO                NO    myalgia,aloc                   
39 4 F B P TIRUNELVELI            11.03.11 18.03.11 INTERM 15 NO NO     NO                NO        NO        NO                NO    abd dist.,facial puff.
40 4 M B P TIRUNELVELI            03.12.09 12.12.09 INTERM 4 NO NO     NO                3episodes NO        NO                2 DAYS NO                             
41 10 F O P SRIVAIKUNDAM           12.12.09 18.12.09 HIGH 4 NO NO     2-3 episodes      NO        NO        NO                2 DAYS NO                             
42 8 F B P KADAYAM                14.12.09 18.12.09 INTERM 7 NO 7 DAYS 5days             NO        NO        NO                5 DAYS NO                             
43 3 M B P KOVILPATTI             01.12.09 08.12.09 INTERM 5 NO NO     NO                NO        NO        NO                3 DAYS NO                             
44 4 F O P TIRUNELVELI            08.12.09 19.12.09 HIGH 7 NO 7 DAYS NO                NO        NO        NO                3 DAYS NO                             
45 7 M F A P RAJAPALAYAM            17.12.09 22.12.09 INTERM 3 NO 4 DAYS NO                NO        2 episodes NO                1 DAY NO                             
46 3 M O P KOVILPATTI             20.12.09 27.12.09 INTERM 15 NO 10 DAYS NO                3 episodes NO        NO                7 DAYS NO                             
47 10 M A P TIRUNELVELI            23.12.09 29.12.09 INTERM 6 NO NO     3 days            NO        NO        NO                2 DAYS NO                             
48 4 M O P KOVILPATTI             11.12.09 20.12.09 INTERM 7 NO 2 DAYS NO                NO        NO        NO                2 DAYS NO                             
49 10 F O P TIRUNELVELI            31.01.10 07.02.10 HIGH 5 NO NO     5 days            NO        1 episode NO                NO    oliguria                       
50 11 M O P TIRUNELVELI            07.04.10 10.04.10 INTERM 7 NO NO     NO                NO        NO        NO                NO    NO                             
51 10 F AB P RAJAPALAYAM            06.10.11 16.10.11 HIGH 6 NO NO     3 days            NO        NO        NO                3 DAYS NO                             
52 8 M B P KOVILPATTI             22.03.10 03.04.10 INTERM 8 NO 4 DAYS 3 days            2 episodes 1 episode NO                3 DAYS NO                             
53 5 F B P AMBAI                  01.11.10 10.11.10 HIGH 10 NO 3 DAYS NO                NO        1 episode NO                3 DAYS NO                             
S.NO SEIZURES PERIPHER FEVER     PALLOR L.PATHY P.EDEMA TORNIQUE RASH PR RR SYS BP DIAS BP UREA SUGAR CREAT. NA K BIL.TOT BIL.DIR BIL.IND SGOT SGPT TOT.PROT
1 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  126 60 100 70 19 97 1.2 140 4.5 1 0.7 0.3 130 160 7.2
2 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE PRESENT 112 30 90 60 19 111 1.2 138 4.9 0.7 0.5 0.2 88 40 7
3 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  100 24 100 70 15 90 0.6 140 3.8 0.9 0.5 0.4 596 138 6.8
4 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  102 22 100 70 47 91 1 138 4 0.5 0.3 0.2 32 17 7
5 NO   WARM      NO FEV    NO     NO        NO        POSITIVE PRESENT 100 24 90 60 25 65 0.7 144 4.4 0.6 0.3 0.3 20 18 7
6 NO   COLD      NO FEV    NO     NO        NO        NEGATIVE ABSENT  90 46 90 60 18 68 1.2 137 4.2 0.8 0.4 0.4 73 31 5.7
7 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE PRESENT 110 26 90 60 38 71 1 134 4 1.2 0.9 0.3 883 340 6.8
8 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  110 28 100 60 40 15 0.8 144 4.2 1 0.5 0.5 339 185 7.5
9 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  136 34 100 70 15 66 0.5 122 4.1 0.9 0.4 0.5 180 100 7
10 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  130 26 100 80 15 92 0.7 137 4.4 0.8 0.4 0.4 110 80 7.4
11 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  110 24 110 70 28 86 0.8 138 3.6 0.8 0.4 0.4 148 118 7.2
12 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  116 26 90 70 15 119 0.7 136 4 0.9 0.6 0.3 23 33 6.8
14 YES  COLD      NO FEV    NO     NO        NO        POSITIVE PRESENT 150 54 NR NR 67 72 0.8 140 4 1 0.6 0.4 370 190 6
15 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE PRESENT 110 32 100 70 20 67 0.8 136 3.7 1.2 0.6 0.6 616 46 6.5
16 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  120 30 100 70 28 86 0.8 138 3.6 0.8 0.4 0.4 148 118 6.2
17 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  110 30 110 70 27 88 1.1 135 4.8 1.2 0.8 0.4 216 72 7.2
18 NO   COLD      NO FEV    NO     NO        NO        NEGATIVE ABSENT  150 32 90 60 51 60 1.1 141 4 1.2 0.6 0.6 116 67 7
19 YES  WARM      FEVER     NO     NO        NO        NEGATIVE PRESENT 140 62 90 60 27 80 1.1 138 4 1.4 0.6 0.8 110 140 6.8
20 YES  WARM      FEVER     NO     NO        NO        NEGATIVE PRESENT 160 30 90 60 24 62 1 138 3.8 1 0.4 0.6 100 140 7
21 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  100 24 100 70 26 118 0.8 142 4.2 0.8 0.4 0.4 145 55 7.3
22 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE PRESENT 106 32 90 70 18 94 0.7 139 4.3 1.4 0.8 0.6 108 70 6.8
23 NO   COLD      NO FEV    NO     NO        NO        NEGATIVE ABSENT  140 60 NR NR 19 309 0.8 140 4.1 1.8 1 0.8 110 80 7
24 NO   WARM      NO FEV    NO     NO        NO        POSITIVE PRESENT 96 24 100 70 20 68 0.6 140 4 1 0.6 0.4 90 70 7.2
25 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  100 30 100 70 17 114 0.9 141 4.2 0.7 0.4 0.3 126 50 5
26 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE PRESENT 96 20 96 68 18 82 0.7 138 3.6 1.2 0.8 0.6 58 48 6.8
27 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  90 20 100 70 21 96 0.8 135 4 1.4 0.7 0.7 110 130 7.2
28 YES  COLD      NO FEV    NO     NO        NO        NEGATIVE ABSENT  170 60 94 60 119 90 1.2 139 4.1 1 0.6 0.4 98 160 6.4
29 NO   WARM      NO FEV    NO     NO        NO        POSITIVE PRESENT 99 20 100 70 23 99 0.8 136 4.2 1.5 1 0.5 176 100 6.9
30 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  90 20 100 70 21 96 0.8 135 4 1.4 0.7 0.7 110 130 7.2
31 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  70 15 90 60 21 76 1.2 145 4 1 0.8 0.2 110 140 8
32 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  96 26 100 70 21 96 1.2 136 4 1 0.8 0.2 110 120 8
33 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  87 23 98 76 18 98 1.2 145 5 1 0.8 0.2 107 114 7.5
34 NO   COLD      NO FEV    NO     NO        NO        NEGATIVE ABSENT  98 20 98 76 51 60 1.1 141 4 1.2 0.6 0.6 116 67 8
35 YES  COLD      FEVER     NO     NO        NO        POSITIVE PRESENT 110 62 70 40 27 60 1.2 138 4 1.4 0.4 1 110 140 6.4
36 NO   COLD      FEVER     YES    NO        YES NEGATIVE ABSENT  110 80 90 70 23 70 1.6 140 5 1.2 0.8 0.4 115 136 6
37 NO   COLD      FEVER     YES    NO        NO        NEGATIVE ABSENT  120 21 100 70 23 96 1.3 145 5.3 1.6 0.8 0.8 110 200 7.6
38 YES  WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  170 40 100 60 88 99 1 140 4.2 0.6 0.4 0.2 110 150 6.1
39 NO   WARM      FEVER     NO     NO        YES NEGATIVE ABSENT  130 36 110 70 16 71 1 140 3.7 0.5 0.3 0.2 34 24 6.7
40 NO   WARM      FEVER     YES    NO        NO        NEGATIVE PRESENT 120 22 90 70 30 70 1 140 4 1 0.8 0.2 110 120 8
41 NO   WARM      FEVER     NO     NO        NO        POSITIVE PRESENT 110 24 100 70 25 68 0.8 140 4 1.4 0.9 0.5 118 100 6.2
42 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  110 28 100 80 28 70 1 138 4.3 1.2 0.8 0.4 130 90 6.8
43 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  100 28 90 70 45 69 0.8 147 4.7 1.1 0.6 0.5 150 100 7
44 NO   WARM      FEVER     NO     NO        NO        NEGATIVE PRESENT 120 30 90 70 33 90 0.9 138 4.2 1.2 0.8 0.4 170 120 7.2
45 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  120 36 80 60 19 75 0.6 136 4.5 1 0.4 0.6 90 80 6.8
46 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  100 30 90 70 18 64 0.6 140 4.5 1 0.7 0.3 2076 724 5.8
47 NO   WARM      FEVER     NO     NO        NO        POSITIVE PRESENT 110 24 100 70 24 70 0.9 140 3.6 1.1 0.5 0.6 90 140 6.8
48 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  100 30 90 70 24 58 0.8 134 3.7 1.4 0.8 0.6 78 110 7
49 NO   COLD      NO FEV    YES    NO        NO        POSITIVE PRESENT 140 40 100 70 56 62 1 140 3.2 2.3 1.5 1 10 15 5.1
50 NO   WARM      NO FEV    NO     NO        NO        NEGATIVE ABSENT  90 24 110 70 30 70 1.4 140 3.6 1 0.5 0.5 160 140 6.4
51 NO   WARM      FEVER     NO     NO        NO        POSITIVE PRESENT 110 26 100 70 25 125 0.9 131 3.4 1.4 0.4 1 180 260 7.4
52 NO   WARM      FEVER     NO     NO        NO        NEGATIVE ABSENT  110 28 100 70 20 78 0.8 140 4.3 1 0.4 0.6 350 300 7
53 NO   WARM      FEVER     NO     NO        NO        NEGATIVE PRESENT 120 24 100 76 26 100 1 138 3.6 1.2 0.6 0.6 340 320 7.4
S.NO ALBUMIN AMYLASE TC DCP DCL DCE HB ESR30 ESR60 PLATELET PCV X RAY CHEST USG ABDOMEN U.ALB U.SUG U.DEP U.CS B.TRANSFUSION DENG.CAT OUTCOME
1 4.2 190 16700 55 45 0 11.7 10 22 180000 36 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
2 4.4 108 4000 50 50 0 10.8 14 24 70000 30 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  1 PLATELET                                  DF RECOVERY
3 4 88 5200 45 52 3 14.3 2 5 43000 44 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
4 4 208 9600 92 5 3 11.6 30 62 100000 33 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
5 3.5 180 4500 27 70 3 15 2 7 23000 47 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  1 PLATELET                                  DHS     RECOVERY
6 3.7 60 8800 31 56 13 12.6 18 67 62000 37 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DSS     RECOVERY
7 4 78 4200 40 60 0 13.1 4 10 36000 41 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  3 PLATELET                                  DF RECOVERY
8 4.5 90 5800 32 68 0 12.3 10 25 78000 38 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
9 4 110 25000 53 40 7 10.9 8 20 34000 37 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
10 4.4 70 6300 34 63 3 11 5 12 35000 40 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
11 4.2 90 6500 27 56 17 11 5 10 101000 43 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
12 4.3 60 5500 42 58 0 14.7 4 9 32000 46 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  2 PLATELET                                  DHS     RECOVERY
14 3.5 80 7000 52 44 4 11 10 18 90000 40 R PF           HEPATOMEGALY   NEG  NEG  NIL  NIL  3 UFFP                                      DSS   DEATH   
15 3.6 94 6000 40 60 0 12 12 24 63000 30 R PF           HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
16 3.8 110 8000 38 60 2 12 10 20 110000 43 R PF           HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
17 4 150 7000 32 66 2 10 8 20 41000 48 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
18 4 114 5000 42 54 4 14.2 20 36 55000 41 NORMAL         NORMAL         NEG  NEG  NIL  NIL  1UBlood                                     DSS RECOVERY
19 3.8 120 21000 33 63 4 11 10 20 23000 33 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  2 PLATELET                                  DSS DEATH   
20 4 110 10000 33 64 3 12 8 18 40000 33 PNEUMONIA      HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
21 4.3 140 6200 30 70 0 11 6 14 28000 51 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  1 PLATELET                                  DHS     RECOVERY
22 3.8 90 5400 34 62 4 10 12 24 90000 40 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
23 4 160 9000 45 55 0 10.5 1 10 20000 31 R PF           R PF ASCITES   TRACE NEG  NIL  NIL  1uFFP&3uPLATELET                            DSS     RECOVERY
24 4.2 150 5400 25 70 5 11.8 10 22 76000 36 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
25 2.3 210 10700 50 42 8 12.2 2 6 23000 36 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  1 PLATELET                                  DF RECOVERY
26 3.8 120 3400 24 72 4 12 15 32 103000 37 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
27 4.2 120 3500 46 52 2 14.4 1 4 254000 44 NORMAL         R PF ASCITES   NEG  POS  NIL  NIL  NIL                                         DHS     RECOVERY
28 3.3 130 5200 49 49 2 10.7 2 4 26000 33 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  3 PLATELET                                  DSS RECOVERY
29 4.1 110 7000 47 52 1 14 1 3 28000 44 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
30 4.2 120 5400 22 74 4 14.4 1 4 254000 44 R PF           R PF ASCITES   NEG  POS  NIL  NIL  NIL                                         DHS     RECOVERY
31 5 100 5200 49 49 2 14 1 3 89000 41 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
32 4 100 7200 39 60 1 16 1 3 85000 41 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
33 4 100 6700 21 78 1 14 1 3 200000 40 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
34 5 112 5800 34 65 1 14.7 1 2 55000 41 NORMAL         NORMAL         NEG  NEG  NIL  NIL  1u whole blood                              DSS     RECOVERY
35 3.1 150 2800 60 37 3 14 1 4 23000 33 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DSS     RECOVERY
36 4 102 20400 78 20 2 14 1 3 62000 37 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DSS     RECOVERY
37 4.3 100 5000 70 26 4 12 1 4 93000 35 NORMAL         NORMAL         NEG  NEG  NIL  NIL  NIL                                         DSS     RECOVERY
38 3.1 112 5400 73 24 3 14.2 5 12 95000 44 PNEUMONIA      R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DSS     RECOVERY
39 3 37 6600 41 53 6 7.5 8 16 80000 26 PNEUMONIA      HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
40 5 110 4800 33 65 2 7 5 8 24000 23 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  1 UFFP                                      DHS     RECOVERY
41 3.2 100 6100 23 75 2 15.7 5 12 22000 47 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  1 PLATELET                                  DHS     RECOVERY
42 3.8 104 7000 20 80 0 12 10 20 76000 37 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
43 4 110 4100 50 48 2 11 22 30 93000 34 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DF      RECOVERY
44 4.2 140 5200 32 66 2 10 10 20 34000 36 R PF           R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
45 3.8 90 6600 17 80 3 10 14 20 58000 32 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
46 2 220 15000 70 24 6 9.3 20 30 112000 28 PNEUMONIA      HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
47 3.8 98 5000 36 60 4 10 12 20 23000 36 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  1 PLATELET                                  DHS     RECOVERY
48 3.8 70 3000 30 68 2 11.2 4 8 95000 44 PNEUMONIA      R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
49 3.1 40 14000 40 45 15 9 30 40 23000 27 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  2u platelet DSS     RECOVERY
50 3.4 123 5100 33 65 2 11.4 5 12 114000 36 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
51 4.2 32 3600 50 46 4 14.8 1 3 20000 45 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  1 PLATELET                                  DHS     RECOVERY
52 4 180 8000 40 58 2 11 10 14 60000 39 NORMAL         HEPATOMEGALY   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
53 4.2 160 12500 39 57 4 14.3 3 10 24000 48 NORMAL         R PF ASCITES   NEG  NEG  NIL  NIL  NIL                                         DHS     RECOVERY
